Matias Nilsson1, Jakob L Poulsen, Christina Brock, Thomas H Sandberg, Mikkel Gram, Jens B Frøkjær, Klaus Krogh, Asbjørn M Drewes. 1. Departments of aGastroenterology and Hepatology bRadiology, Mech-Sense, Aalborg University Hospital cDepartment of Clinical Medicine, Aalborg University, Aalborg dDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen eNeurogastroenterology Unit, Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
Abstract
OBJECTIVE: Opioid treatment is associated with numerous gastrointestinal adverse effects collectively known as opioid-induced bowel dysfunction (OIBD). Most current knowledge of the pathophysiology derives from animal studies limited by species differences and clinical studies, which have substantial confounders that make evaluation difficult. An experimental model of OIBD in healthy volunteers in a controlled setting is therefore highly warranted. The aim of this study was to assess bowel function in healthy volunteers during opioid treatment using subjective and objective methods. METHODS:Twenty-five healthy men were assigned randomly to oxycodone or placebo for 5 days in a cross-over design. The analgesic effect was assessed with muscle pressure algometry and adverse effects were measured using questionnaires including the bowel function index, gastrointestinal symptom rating scale, patient assessment of constipation symptoms and the Bristol stool form scale. Colorectal volumes were determined using a newly developed MRI method. RESULTS: Compared with baseline, oxycodone increased pain detection thresholds by 8% (P=0.02). Subjective OIBD was observed as increased bowel function index (464% increase; P<0.001), gastrointestinal symptom rating scale (37% increase; P<0.001) and patient assessment of constipation symptoms (198% increase; P<0.001). Objectively, stools were harder and drier during oxycodone treatment (P<0.001) and segmental colorectal volumes increased in the caecum/ascending colon by 41% (P=0.005) and in the transverse colon by 20% (P=0.005). No associations were detected between questionnaire scores and colorectal volumes. CONCLUSION: Experimental OIBD in healthy volunteers was induced during oxycodone treatment. This model has potential for future interventional studies to discriminate the efficacies of different laxatives, peripheral morphine antagonists and opioid treatments.
RCT Entities:
OBJECTIVE: Opioid treatment is associated with numerous gastrointestinal adverse effects collectively known as opioid-induced bowel dysfunction (OIBD). Most current knowledge of the pathophysiology derives from animal studies limited by species differences and clinical studies, which have substantial confounders that make evaluation difficult. An experimental model of OIBD in healthy volunteers in a controlled setting is therefore highly warranted. The aim of this study was to assess bowel function in healthy volunteers during opioid treatment using subjective and objective methods. METHODS: Twenty-five healthy men were assigned randomly to oxycodone or placebo for 5 days in a cross-over design. The analgesic effect was assessed with muscle pressure algometry and adverse effects were measured using questionnaires including the bowel function index, gastrointestinal symptom rating scale, patient assessment of constipation symptoms and the Bristol stool form scale. Colorectal volumes were determined using a newly developed MRI method. RESULTS: Compared with baseline, oxycodone increased pain detection thresholds by 8% (P=0.02). Subjective OIBD was observed as increased bowel function index (464% increase; P<0.001), gastrointestinal symptom rating scale (37% increase; P<0.001) and patient assessment of constipation symptoms (198% increase; P<0.001). Objectively, stools were harder and drier during oxycodone treatment (P<0.001) and segmental colorectal volumes increased in the caecum/ascending colon by 41% (P=0.005) and in the transverse colon by 20% (P=0.005). No associations were detected between questionnaire scores and colorectal volumes. CONCLUSION: Experimental OIBD in healthy volunteers was induced during oxycodone treatment. This model has potential for future interventional studies to discriminate the efficacies of different laxatives, peripheral morphine antagonists and opioid treatments.
Authors: H Halawi; P Vijayvargiya; I Busciglio; I Oduyebo; D Khemani; M Ryks; D Rhoten; D Burton; L A Szarka; A Acosta; M Camilleri Journal: Neurogastroenterol Motil Date: 2018-02-06 Impact factor: 3.598
Authors: Adam D Farmer; Asbjørn M Drewes; Giuseppe Chiarioni; Roberto De Giorgio; Tony O'Brien; Bart Morlion; Jan Tack Journal: United European Gastroenterol J Date: 2018-12-14 Impact factor: 4.623
Authors: Jakob L Poulsen; Esben B Mark; Christina Brock; Jens B Frøkjær; Klaus Krogh; Asbjørn M Drewes Journal: J Neurogastroenterol Motil Date: 2018-01-30 Impact factor: 4.924
Authors: Joseph V Pergolizzi; Robert B Raffa; Marco Pappagallo; Charles Fleischer; Joseph Pergolizzi; Gianpietro Zampogna; Elizabeth Duval; Janan Hishmeh; Jo Ann LeQuang; Robert Taylor Journal: Patient Prefer Adherence Date: 2017-01-17 Impact factor: 2.711
Authors: Anne E Olesen; Debbie Grønlund; Esben B Mark; Klaus Krogh; Jens B Frøkjær; Asbjørn M Drewes Journal: J Neurogastroenterol Motil Date: 2019-10-30 Impact factor: 4.924